Browse by category

Novo Nordisk announced the submission of a sNDA to the FDA for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA's acceptance of the filing. The sNDA includes results from STEP UP, a 72-week phase 3, randomised, double-blind, placebo-controlled and active-control